Biomarkers for determining the prognosis in chronic myelogenous leukemia

The introduction of BCR-ABL1 tyrosine kinase inhibitors (TKIs) for treatment of chronic myelogenous leukemia in chronic phase (CML-CP) has revolutionized therapy, altering the outcome from one of shortened life expectancy to long-term survival. With over 10 years of long-term treatment with imatinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Sweet, Kendra, Zhang, Ling, Pinilla-Ibarz, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3737033/
https://www.ncbi.nlm.nih.gov/pubmed/23870290
http://dx.doi.org/10.1186/1756-8722-6-54

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3737033/
https://www.ncbi.nlm.nih.gov/pubmed/23870290
http://dx.doi.org/10.1186/1756-8722-6-54

Ejemplares similares